English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 1 April 2022, 14:05 JST
Share:
    

Source: Eisai
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business

TOKYO, Apr 1, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares issued by Arteryex Inc., a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party allocation of common shares, and made it a subsidiary, as of March 31, 2022. The two companies will work together to develop and provide PHR (Personal Health Record)-related services for patients, healthcare professionals and society at large.

Eisai launched its medium-term business plan "EWAY Future & Beyond" in April 2021, where the perspective to be shifted from that of patients to The People or each consumer. With "empowering The People to realize their fullest life" as the vision, Eisai delivers not only pharmaceutical products but also solutions to The People, by utilizing the latest digital technology such as AI, and aims to remove the anxiety of The People.

Arteryex has excellent software development capabilities and has developed its own PHR-related product services, including apps for storing and converting health-related information of patients undergoing treatment and a wide range of users into data, as well as apps for companies for employee health management.

Eisai aims to strengthen and rapidly expand its digital solution business base by acquiring Arteryex's development capabilities and quality PHR products through the subsidiary acquisition. In addition to reaching a new customer segment of existing products, Eisai will promote developing products including new applications by utilizing Arteryex's input technology and systems used in image data. Furthermore, Eisai will advance the utilization of data acquired through PHR-related products, as the entire Eisai Group, leveraging the data management know-how that Eisai has practiced in its medicine creation activities and disease awareness activities.

For building the Eisai Universal Platform (EUP), through those initiatives, Eisai will enhance creating a packaged solution, as well as strengthen its delivery infrastructure, for maintenance and improvement of health, prevention and disease awareness, and will expand its contribution to The People.

The current management team of Arteryex will remain after the conversion to a subsidiary. The acquisition by Eisai of Arteryex as a subsidiary will not have a material impact on the consolidated financial results of Arteryex.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Topic: Press release summary
Source: Eisai

Sectors: MedTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Thursday, 1 December 2022, 20:09 JST
Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
2022年12月1日 8時30分 JST
エーザイ、サンアントニオ乳がんシンポジウム2022におけるエリブリンの前臨床および臨床研究に関する演題について発表
2022年11月30日 17時30分 JST
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」の早期アルツハイマー病に対する臨床第III相Clarity AD検証試験結果を第15回アルツハイマー病臨床試験会議(CTAD)において発表
2022年11月30日 17時30分 JST
エーザイ、11名の先端医療機関の専門家および8名のエーザイ研究者による「レカネマブ」の早期アルツハイマー病に対する臨床第III相Clarity AD検証試験結果の論文がthe New England Journal of Medicineに掲載
Wednesday, 30 November 2022, 10:21 JST
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575